Research and Product Records: Source Index

1. Read states used in this collection

• Full page read. The public page was read in full on 2026-11-13, and the statements attributed to it come from that reading.
• Abstract read; full text not reviewed. The summary was read; the article body was not.
• Lead only. A search result or citation was seen, but the underlying document was not opened.
• Metadata and headings only. The page title, URL and stated role were used; the body was not re-read for this package.

These states are not interchangeable. A claim supported by an abstract is weaker than one supported by a full text, and a lead is not support at all.

2. Product listings

All six were read in full on 2026-11-13. They are public product pages derived from manufacturer materials; they are not test reports or certificates. Codes in brackets are the citation keys used in the chapters.

• ^[1] Mugwort Soothing Balm, 20 g Tin. moxasourcing.com/catalog-item/mugwort-botanical-balm-20g-packaging-reference/
• ^[2] Herbal Massage Balm 50 g and Roll-On Liquid 50 ml. moxasourcing.com/catalog-item/botanical-massage-paste-liquid-reference/
• ^[3] Herbal Roll-On Liquid, 50 ml. moxasourcing.com/catalog-item/botanical-roll-on-liquid-reference-50ml/
• ^[4] Sanqi Botanical Red-Paste Patches, 12 per Box. moxasourcing.com/catalog-item/sanqi-botanical-red-paste-patches-12-per-box/
• ^[5] Safflower & Mugwort Patches, 7 per Box. moxasourcing.com/catalog-item/safflower-mugwort-non-heating-patches-7-box-10x13cm/
• ^[6] Mugwort Bone-Penetrating Patch, 12 per Box. moxasourcing.com/catalog-item/mugwort-botanical-adhesive-patches-12-box/

Each has a documented limitation. MS-CAT-29D5D09B3B does not state species, part or strength. MS-CAT-75A3663FE7 contains a material field (“mugwort”) that its own ingredient declaration does not support, and gives no roll-on formula. MS-CAT-04321578D7 carries two conflicting direction panels. MS-CAT-ADBE39E4F2 carries conflicting heating and weight fields. MS-CAT-49819BAC9D combines a not-self-heating field with warm-moxibustion language and a shared pouch. MS-CAT-0C0A4A2DC9 states no shelf life and uses a product name that is not a mechanism. The chapters preserve these limitations rather than resolving them by assumption.

3. Discussion records

Six public discussion records were read on 2026-11-13. None is a verified buyer, a clinical case or a demand estimate. Two relate directly to mugwort (D05 and P19Q01); four are adjacent.

• [D05] “Mugwort/Moxa Patches”, r/ChineseMedicine. reddit.com/r/ChineseMedicine/comments/1skqw4b/mugwortmoxa_patches/ — direct mugwort patch question; identity, organic wording, adhesion, irritation anecdote. A cross-post to r/herbalism is the same question and is not counted separately.
• [P19Q01] “Chronic pain — herbs that might help?”, r/herbalism. reddit.com/r/herbalism/comments/16iym31/chronic_pain_herbs_that_might_help/ — a multi-herb olive-oil balm experience; not an isolated mugwort evaluation.
• [P19Q02] “Pain relieving sprays recommends?”, r/ankylosingspondylitis. reddit.com/r/ankylosingspondylitis/comments/1wvvwoz/pain_relieving_sprays_recommends/ — adjacent spray question; supports the reach concern, not a mugwort spray.
• [P19Q03] “Are Pain Relief Patches Supposed to Feel Like a Burn?”, r/ChronicPain. reddit.com/r/ChronicPain/comments/1kqx9h7/are_pain_relief_patches_supposed_to_feel_like_a/ — a drug patch, not a mugwort product; used for the question only.
• [P19Q04] “Massage salves?”, r/massage. reddit.com/r/massage/comments/1msv0i8/massage_salves/ — adjacent; supports jar handling and residue concerns.
• [P19Q05] “Good topical creams?”, r/Supplements. reddit.com/r/Supplements/comments/1tjymdv/good_topical_creams/ — adjacent; odour, burning and grease concerns; author identity and motive unverified.

4. External records

• [K01] FDA National Drug Code Directory. fda.gov — National Drug Code Directory. Original page read. A directory of listings, not an approval or efficacy record.
• [K02] DailyMed, “Mugwort Pain Relief Patch” label archive. dailymed.nlm.nih.gov. Original page read. A submitted label; the page shows an inactive code; not an endorsement.
• [K03] Basiri Z, Zeraati F, Esna-Ashari F, et al. Topical effects of Artemisia absinthium ointment and liniment compared with piroxicam gel in knee osteoarthritis: a randomised double-blind controlled trial. Iranian Journal of Medical Sciences 2017;42(6):524–531. PMID 29184260; PMC5684373. pubmed.ncbi.nlm.nih.gov/29184260/. Abstract read via Europe PMC; full text not reviewed.
• [K05] ISO 16128-1:2016, Guidelines on technical definitions and criteria for natural and organic cosmetic ingredients and products — Part 1: Definitions for ingredients. iso.org/standard/62503.html. Official abstract read; full standard not acquired. Scope is ingredient definitions; the abstract states that it does not address claims, labelling, safety, packaging or regulatory requirements.
• [K06] U.S. Food and Drug Administration, “Organic” Cosmetics. fda.gov/cosmetics/cosmetics-labeling-claims/organic-cosmetics. Full page read. States that FDA has no definition of “organic” for cosmetics, that USDA NOP defines and certifies organic agricultural ingredients and labelling percentages, and that organic claims must comply with both USDA and FDA requirements.
• [K04] FDA pharmacovigilance review of a topical analgesic patch (2016). fda.gov/media/100045/download. Lead only; full PDF not reviewed. A specific product and historical review, not a general safety standard.

5. Cross-topic method pages

These pages were not re-read in full for this package. Their titles, URLs and stated roles were used, and no parameters were migrated from them into P19.

• P09: Neck Warming Patch Quality Testing; Monthly Heat Patch Specification.
• P13: Hydrosol Packaging Tests: Spray, Leaks, Stability; 100 mL Mugwort Hydrosol.
• P12: Mugwort Body Oil vs Essential Oil; How to Test a 20 ml Mugwort Body Oil Sample.
• C02–C06: Wholesale, Private Label or Managed Sourcing; Brief and Sample Plan; Sample Evaluation Scorecard; Approved Sample to Bulk Order; Documents Checklist; Classification Before Claims; Order Responsibility.
• P03: How to read moxibustion research.

6. What is not in this index

• No mugwort pain-spray product file was located.
• No direct question about a mugwort pain spray was located.
• K03 was read in full through PubMed Central; K04 remains a lead. The ISO 16128-1 full standard was not acquired; only its official abstract was read.
• No certification, test report or batch record for any of the six listings was available.
• No search-volume, AI-citation or commercial outcome data was observed.

Those absences define the limits of the collection. They are recorded here so that a reader does not have to infer them from what is missing.

7. Technical and safety sources

The following sources support the linked explanations within their stated scopes. Capturing a document is not the same as reviewing all its sections; the read extent is recorded for each source.

• FDA transdermal/topical delivery-system draft (2019) — Selected background, structure, product-quality and component sections; matrix illustration. Draft, not for implementation; medicinal carrier-device scope. Additional selected adhesion/cold-flow and specimen discussions on printed pages20–22 were reviewed.
• EMA cutaneous-product quality and equivalence guideline (2024) — Selected scope and development/control sections; openings of release/permeation annexes. Chemical-medicine scope; herbal medicines excluded from therapeutic-equivalence section.
• FDA Microbiological Safety and Cosmetics — Relevant contamination and handling sections. US cosmetic information; not a validated professional shared-use protocol.
• FDA Product Testing of Cosmetics — Relevant testing and microbiological-quality sections; no approval or testing of the reference products.
• Jow Liniment, external commercial example — Product description, declared composition, directions and cautions. Source spelling retained; not an own supply SKU or clinical result.
• Protection Liniment, external commercial example — Product description and declared multi-herb composition; no own supply or efficacy verification.
• Health Canada topical pain-reliever safety review (2017) — Review body, findings and conclusions. Ingredient-specific safety assessment; historical report counts are not incidence.
• Desai et al. case report (2021) — Case presentation and discussion. One different menthol/methyl-salicylate ointment case with diabetes/neuropathy; not mugwort causation or a risk frequency.
• EMA herbal declaration guideline, Revision 1 (2010) — Selected scope, preparation declarations, definitions and labelling annex. Effective version checked separately from the 2026 draft; medicinal declaration examples, not mugwort specifications.
• EMA herbal-quality guideline, Revision 3 (2022) — Scope and sections 3.1–3.2.4. Medicinal preparation, marker and composition terminology; not classification or conformity of our references.
• DailyMed Salonpas Pain Relieving Jet label, version12 (2025) — Label metadata, Drug Facts, strength, packaging and archive fields read. Adjacent non-mugwort aerosol; no own supply, approval inference or transferred instructions.
• USDA body-care organic eligibility — Body-care eligibility and certification-chain overview read. Conditional US NOP scope; no reference-product certification verified.
• USDA organic-labelling overview — Relevant certification, panel, category and exemption sections read. Percentage thresholds alone do not approve a formula or claim.
• 7 CFR 205.404, certification — Selected certificate/addendum/status clauses read in official eCFR, displayed current through November10,2026. No particular operation checked.
• FDA Allergens in Cosmetics — Consumer ingredient/claim guidance read; no reference-formula classification or individual tolerance finding.
• FDA Hypoallergenic Cosmetics — Current introduction and historical discussion distinguished; historical proposed testing rule is not a current universal requirement.

K27 — 7 CFR 205.207. US wild-crop organic harvesting rule; no reference-product claim verified.

K28 — EMA GACP 2025 final. Herbal starting materials for herbal medicinal products; sections 2–14 read; no reference chain audited.

K29 — FDA Q3 2026 final. Topical drug ANDAs; sections I–IV read; not Q3 quality-control guidance or a classification/BE decision for reference products.

K30 — EMA herbal specifications Rev.3 (2022). Selected identity, assay, reference-material and impurity sections; medicinal scope.

K31 — FDA adhesion guidance (July 2026 final). ANDA medicinal systems; sections I–V and original scale reviewed.

K32 — FDA irritation/sensitization (July 2026 revised draft). Not for implementation; selected study-purpose, conduct and adverse-event sections.

K33 — FDA BAM Chapter23 (July 2024). Cosmetics methods, selected sample handling/preparation and findings/preservation; no reference classification.

K34 — FDA Botanical Drug Development (2016 final). Selected scientific consistency, prior-experience, clinical-batch and analytical sections; not a current market-entry legal summary.